Total Funding
11
19
Total FundingPrivate Equity raised
Growth Score
-11 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
317218
IV Diagnostics develops diagnostic tools for detecting, measuring and monitoring rare circulating tumor cells.
John D. Feczko: Chief Science Officer & VP- Sarah Ware: CEO
About the Company
Cancer cells spread through the circulatory system as “circulating tumor cells” (CTCs) and represent unique diagnostic targets. CTCs are released from primary tumors into blood circulation and then lodge at distant organs to initiate new cancer growth. Thus circulating tumor cells constitute the major cause for mortality among cancer patients.
Recent advancements in detection and characterization of CTCs can have a significant impact on early cancer detection. For instance, the quantization of CTCs can be used for prognosis of the outcomes of metastatic diseases. In another example, identification of cancer stem cells, a subpopulation of CTCs believed to be tumorigenic, can be used for identifying metastasis and recurrence of disease.
Women Founded
